Another study has demonstrated that the use of incretin enhancers (DPP-4 inhibitors) and mimetics (GLP-1 agonists) alone, without combination with sulfonylurea, has a low risk of resulting in hypoglycemia [50]. Here, DPP4 is linked to Hypoglycemia.